Package Leaflet: Information for the Patient
QUVIVIQ 25 mg film-coated tablets
QUVIVIQ 50 mg film-coated tablets
daridorexant
This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of this leaflet includes information on how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
QUVIVIQ contains the active substance called daridorexant, which belongs to a class of medicines called «orexin receptor antagonists».
QUVIVIQ is used to treat insomnia in adults.
How QUVIVIQ works
Orexin is a substance produced by the brain that helps keep you awake. By blocking the action of orexin, QUVIVIQ helps you fall asleep faster, sleep longer, and improves your ability to function normally during the day.
Do not take QUVIVIQ
Ask your doctor if the medicine you are taking prevents you from taking QUVIVIQ.
Warnings and precautions
Consult your doctor or pharmacist before starting QUVIVIQ:
Your doctor may want to monitor how the medicine affects you.
Talk to your doctor if you experience any of the following side effects while taking QUVIVIQ:
If you suffer from depression and experience worsening or have thoughts of self-harm, contact your doctor immediately.
Children and adolescents
This medicine is not for children and adolescents under 18 years old because QUVIVIQ has not been tested in this age group.
Other medicines and QUVIVIQ
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, because:
Taking QUVIVIQ with food, drinks, and alcohol
Taking alcohol with QUVIVIQ may increase the risk of balance and coordination disorders.
Avoid taking grapefruit or grapefruit juice at night, as it may increase QUVIVIQ levels in the blood.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before taking this medicine.
It is not known if QUVIVIQ can harm the fetus.
A small amount of QUVIVIQ passes into breast milk. Consult your doctor on the best way to feed your baby during treatment with QUVIVIQ.
It is not known if QUVIVIQ affects human fertility.
Driving and using machines
It is recommended that a period of approximately 9 hours elapses between taking QUVIVIQ and driving or using machines. Be careful when driving or using machines in the morning after taking QUVIVIQ. Do not engage in potentially hazardous activities if you are not sure you are fully awake, especially shortly after waking up in the first days of treatment.
QUVIVIQ contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially “sodium-free”.
Follow the instructions for administration of this medicine exactly as prescribed by your doctor. If you are unsure, consult your doctor or pharmacist again.
How much QUVIVIQ to take
Your doctor will inform you of the dose of QUVIVIQ you should take.
The recommended dose is one 50 mg QUVIVIQ tablet per night.
If you have liver problems or are taking certain medicines, your doctor may prescribe a lower dose, one 25 mg QUVIVIQ tablet per night.
The duration of treatment should be as short as possible. After 3 months, your doctor will periodically reassess the need to continue treatment.
If you take more QUVIVIQ than you should
If you have taken too much QUVIVIQ, you may experience excessive sleepiness and muscle weakness. Contact your doctor immediately.
If you forget to take QUVIVIQ
If you forget to take QUVIVIQ at bedtime, do not take it later during the night, or you may feel drowsy the next morning. Do not take a double dose to make up for forgotten tablets.
If you stop taking QUVIVIQ
Treatment with QUVIVIQ can be stopped without the need to gradually reduce the dose, and without harmful effects.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may occur with this medicine:
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
If you experience any of these side effects, tell your doctor.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after ‘EXP’.
The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of QUVIVIQ
The active substance is daridorexant.
QUVIVIQ 25 mg film-coated tablets
Each tablet contains daridorexant hydrochloride, equivalent to 25 mg of daridorexant.
QUVIVIQ 50 mg film-coated tablets
Each tablet contains daridorexant hydrochloride, equivalent to 50 mg of daridorexant.
The other ingredients are:
Core of the tablet: mannitol (E421), microcrystalline cellulose (E460), povidone, sodium croscarmellose (see section 2 ‘QUVIVIQ contains sodium’), silicon dioxide, magnesium stearate
Coating: hypromellose (E464), microcrystalline cellulose (E460), glycerol, talc (E553), titanium dioxide (E171), red iron oxide (E172), black iron oxide (E172), yellow iron oxide (E172; only for 50 mg tablets).
Appearance and packaging
Film-coated tablet (tablet)
QUVIVIQ 25 mg film-coated tablets
Light purple triangular tablet with «25» engraved on one side and «i» (Idorsia logo) on the other.
QUVIVIQ 50 mg film-coated tablets
Light orange triangular tablet with «50» engraved on one side and «i» (Idorsia logo) on the other.
QUVIVIQ is available in blister packs containing 10, 20, or 30 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder
Idorsia Pharmaceuticals Deutschland GmbH
Marie-Curie-Strasse 8
79539 Lörrach
Germany
Manufacturer
Idorsia Pharmaceuticals Deutschland GmbH
Marie-Curie-Strasse 8
79539 Lörrach
Germany
PharmaKorell GmbH
Georges-Koehler-Str. 2
79539 Lörrach
Germany
Date of last revision of this leaflet 06/2023
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.